Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer (RNA-seq)

PROVIDER: PRJNA318925 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3403860.fastq.gz	Fastqsanger.gz
	SRR3403870.fastq.gz	Fastqsanger.gz
	SRR3403861.fastq.gz	Fastqsanger.gz
	SRR3403871.fastq.gz	Fastqsanger.gz
	SRR3403862.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Homo sapiens

Project description:Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer (ChIP-seq)

| PRJNA318399 | ENA

Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer

Project description:Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer

| PRJNA318923 | ENA

Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC [RNA-seq]

Project description:Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC [RNA-seq]

| PRJNA880856 | ENA

Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer

Project description:Here we report the identification of bruceantin as a highly potent inhibitor of HSP90. RNA-seq analysis demonstrated bruceantin inhibits the transcriptional activity of androgen receptor and androgen receptor variant 7 and downregulates their target genes in castration-resistant prostate cancer cells.

2021-02-24 | GSE145790 | GEO

Homo sapiens

Project description:Inhibition of Androgen Receptor and β-catenin activity in prostate cancer

| PRJNA213558 | ENA

SPOP mutation - SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling

Project description:Recurrent point mutations in SPOP define a distinct molecular subclass of prostate cancer. Here, we describe the first mouse model showing that mutant SPOP drives prostate tumorigenesis in vivo. Conditional expression of mutant SPOP in the prostate dramatically altered phenotypes in the setting of Pten loss, with early neoplastic lesions (high-grade prostatic intraepithelial neoplasia) with striking nuclear atypia, and invasive poorly differentiated carcinoma. In mouse prostate organoids, mutant SPOP drove increased proliferation and a transcriptional signature consistent with human prostate cancer. Using these models and human prostate cancer samples, we show that SPOP mutation activates both PI3K/mTOR and androgen receptor (AR) signaling, effectively uncoupling the normal negative feedback between these two pathways. Associated RNA-seq data deposited in GEO: GSE94839.

2017-03-20 | PXD005309 | Pride

Contribution of UPF1 and RCOR1 to androgen response of prostate cancer cells.

Project description:The ligand-activated androgen receptor is a transcription factor that drives prostate cancer growth. Blocking androgen-activation of androgen receptor via androgen deprivation therapy is the default treatment for metastatic prostate cancer. Despite initial remissions, androgen deprivation invariably fails and prostate cancer progresses to castration-recurrent disease, which still relies on aberrantly activated androgen receptor. Alternative approaches are needed to inhibit androgen receptor action in prostate cancer that has failed androgen deprivation therapy. Our laboratory has been exploring the therapeutic potential of a non-canonical androgen receptor signaling mechanism wherein androgen receptor stimulates another transcription factor, Serum Response Factor. Serum Response Factor-mediated androgen receptor action correlates with prostate cancer progression and is enriched in castration-recurrent prostate cancer. Inhibiting Serum Response Factor-dependent androgen receptor action may be an effective treatment strategy following failure of androgen deprivation therapy but remains poorly understood. We have recently isolated UPF1 and RCOR1 as putative novel mediators of Serum Response Factor-dependent androgen receptor action. Here, we perform RNA-Seq assays to determine the contribution of UPF1 and RCOR1 to the androgen response of prostate cancer cells.

2025-05-15 | GSE248034 | GEO

Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer [RNA-seq]

Project description:Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer [RNA-seq]

| PRJNA844003 | ENA

Prostate Cancer Risk SNPs in Androgen Receptor Target Sites

Project description:We profiled androgen receptor (AR) genomic targets using high-throughput sequencing of chromatin-immunoprecipitated (ChIP) DNA from TMPRSS2-ERG fusion gene positive DUCaP prostate cancer cells. ChIp-seq and microarray gene expression profiling datasets were integrated with the NHGRI GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor binding sites (ARBSs). Eighty GWAS index or linked SNPs were found to be localized in ARBSs. Among these rs11891426:T>G in the 7th intron of the melanophilin gene was found located within a novel putative auxiliary AR binding motif, which we found enriched in the neighborhood of canonical androgen responsive elements. T→G exchange attenuated the transcriptional activity of the ARBS in an AR reporter gene assay of prostate cancer cell models. It went also in line with decreased melanophilin protein level in primary prostate tumors with G allele.These results unravel a hidden link between androgen receptor and a functional PCa risk SNP, whose allele alteration affects androgen regulation of its host gene melanophilin . Genomic profile of androgen receptor binding sites of androgen or vehicle treated DUCaP cells using ChIP-seq. IgG precipiated DNAs from both treatments served as controls.

2015-07-10 | E-GEOD-70679 | biostudies-arrayexpress

SMAD3 promotes the expression and activity of androgen receptor in prostate cancer [RNA-seq]

Project description:SMAD3 promotes the expression and activity of androgen receptor in prostate cancer [RNA-seq]

| PRJNA873038 | ENA